Cargando…

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

Immune checkpoint blockade therapies (ICBTs) targeting programmed cell death 1 (PD-1) and its ligand programmed death ligand-1 (PD-L1/B7-H1/CD274) have exhibited momentous clinical benefits and durable responses in multiple tumor types. However, primary resistance is found in considerable number of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yiting, Wang, Huanbin, Yao, Han, Li, Chushu, Fang, Jing-Yuan, Xu, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992436/ https://www.ncbi.nlm.nih.gov/pubmed/29910728 http://dx.doi.org/10.3389/fphar.2018.00536

Ejemplares similares

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Editorial: Targeting the PD-1/PD-L1 cancer immune evasion axis: Challenges and emerging strategies, Volume II
por: He, Xiujing, et al.
Publicado: (2022)

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy
por: Yao, Han, et al.
Publicado: (2018)

THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy
por: Li, Chushu, et al.
Publicado: (2021)

Acetylation in Tumor Immune Evasion Regulation
por: Lu, Jun, et al.
Publicado: (2021)

A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions
por: Yao, Han, et al.
Publicado: (2020)

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
por: Kim, Seong Keun, et al.
Publicado: (2022)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Traditional Chinese Medicine Pien-Tze-Huang Inhibits Colorectal Cancer Growth and Immune Evasion by Reducing β-catenin Transcriptional Activity and PD-L1 Expression
por: Chen, Qiang, et al.
Publicado: (2022)

Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer
por: Cen, Bo, et al.
Publicado: (2021)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target
por: Zhou, Junzhi, et al.
Publicado: (2023)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers
por: Yu, Zheng-Zheng, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
por: Zhu, Qiang, et al.
Publicado: (2023)

Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
por: Timaner, Michael, et al.
Publicado: (2019)

Upregulation of PD‐L1 by SARS‐CoV‐2 promotes immune evasion
por: Huang, Hsiang‐Chi, et al.
Publicado: (2023)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

Glycolytic enzyme HK2 promotes PD-L1 expression and breast cancer cell immune evasion
por: Lin, Jichun, et al.
Publicado: (2023)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes
por: Zheng, Dan, et al.
Publicado: (2022)

CRISPR screening identifies the deubiquitylase ATXN3 as a PD-L1–positive regulator for tumor immune evasion
por: Wang, Shengnan, et al.
Publicado: (2023)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC
por: Zhou, Kai-Xia, et al.
Publicado: (2021)

PD-L1 translocation to the plasma membrane enables tumor immune evasion through MIB2 ubiquitination
por: Yu, Xinfang, et al.
Publicado: (2023)

Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism
por: Raftery, Martin J., et al.
Publicado: (2018)

PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy
por: Xu, Yiqi, et al.
Publicado: (2021)

Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion
por: Dong, Peixin, et al.
Publicado: (2018)

DENR controls JAK2 translation to induce PD-L1 expression for tumor immune evasion
por: Chen, Baiwen, et al.
Publicado: (2022)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
por: Du, Linyong, et al.
Publicado: (2020)

RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination
por: Zhang, Yangyang, et al.
Publicado: (2023)

Colorectal Cancer‐Derived Small Extracellular Vesicles Promote Tumor Immune Evasion by Upregulating PD‐L1 Expression in Tumor‐Associated Macrophages
por: Yin, Yuan, et al.
Publicado: (2022)

RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion
por: Zhang, Yanyan, et al.
Publicado: (2022)

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
por: Ricklefs, Franz L., et al.
Publicado: (2018)

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
por: Juneja, Vikram R., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_emnaqvkpnpbedrhj1poogfknqm